- Home
- ANEB vs SERA Comparison
ANEB vs SERA Comparison
Compare ANEB & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- SERA
- Stock Information
- Founded
- ANEB 2020
- SERA 2008
- Country
- ANEB United States
- SERA United States
- Employees
- ANEB N/A
- SERA N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- SERA Precision Instruments
- Sector
- ANEB Health Care
- SERA Health Care
- Exchange
- ANEB Nasdaq
- SERA Nasdaq
- Market Cap
- ANEB 98.6M
- SERA 90.6M
- IPO Year
- ANEB 2021
- SERA 2021
- Fundamental
- Price
- ANEB $2.28
- SERA $3.21
- Analyst Decision
- ANEB Buy
- SERA
- Analyst Count
- ANEB 2
- SERA 0
- Target Price
- ANEB $8.00
- SERA N/A
- AVG Volume (30 Days)
- ANEB 124.0K
- SERA 58.6K
- Earning Date
- ANEB 11-12-2025
- SERA 11-05-2025
- Dividend Yield
- ANEB N/A
- SERA N/A
- EPS Growth
- ANEB N/A
- SERA N/A
- EPS
- ANEB N/A
- SERA N/A
- Revenue
- ANEB N/A
- SERA $108,000.00
- Revenue This Year
- ANEB N/A
- SERA $217.92
- Revenue Next Year
- ANEB N/A
- SERA $479.25
- P/E Ratio
- ANEB N/A
- SERA N/A
- Revenue Growth
- ANEB N/A
- SERA 0.94
- 52 Week Low
- ANEB $0.80
- SERA $1.37
- 52 Week High
- ANEB $3.42
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- ANEB 42.33
- SERA 56.31
- Support Level
- ANEB $2.34
- SERA $2.87
- Resistance Level
- ANEB $2.47
- SERA $3.29
- Average True Range (ATR)
- ANEB 0.12
- SERA 0.21
- MACD
- ANEB -0.02
- SERA -0.00
- Stochastic Oscillator
- ANEB 13.49
- SERA 59.52
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.